A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 18, 2019

Primary Completion Date

December 30, 2019

Study Completion Date

December 30, 2019

Conditions
Acute Myeloid LeukemiaNon-Hodgkin's LymphomaDiffuse Large B-cell Lymphoma
Interventions
DRUG

Venetoclax

tablet, oral

DRUG

AMG 176

solution, intravenous

Trial Locations (17)

2298

Calvary Mater Newcastle /ID# 211455, Waratah

3004

Alfred Health /ID# 210350, Melbourne

5000

Royal Adelaide Hospital /ID# 210602, Adelaide

13353

Charite Universitaetsklinikum Berlin - Campus Virchow /ID# 207987, Berlin

15232

UPMC Hillman Cancer Ctr /ID# 208482, Pittsburgh

20246

Universitaetsklinikum Hamburg-Eppendorf (UKE) /ID# 207788, Hamburg

27599

Unc /Id# 207388, Chapel Hill

52242

University of Iowa Hospitals and Clinics /ID# 207459, Iowa City

60590

Universitaetsklinikum Frankfurt /ID# 207984, Frankfurt am Main

63110

Washington University-School of Medicine /ID# 206995, St Louis

66160

Univ Kansas Med Ctr /ID# 207480, Kansas City

90033

USC Norris Cancer Center /ID# 207396, Los Angeles

91010

City of Hope /ID# 207393, Duarte

02215

Duplicate_Dana-Farber Cancer Institute /ID# 207367, Boston

10016-6402

NYU Langone Medical Center /ID# 207390, New York

04103

Universitaetsklinikum Leipzig /ID# 209824, Leipzig

01307

Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 207803, Dresden

Sponsors

Lead Sponsor

Collaborators (2)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Amgen

INDUSTRY

lead

AbbVie

INDUSTRY